Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
Sorafenib is a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). These patients may simultaneously receive anti-hepatitis B treatment if they are viremic. The <i>N-Acetylgalactosaminyltransferase 14</i> (<i>GALNT14</i>) gene can serve as a biomar...
Enregistré dans:
| Auteurs principaux: | Kung-Hao Liang, Sung-Fang Chen, Yu-Hua Lin, Yu-De Chu, Yang-Hsiang Lin, Ming-Wei Lai, Chih-Lang Lin, Chau-Ting Yeh |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
MDPI AG
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/561db4041fd940c886045ef37ad752e0 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
par: Sara Jeong, et autres
Publié: (2021) -
Tenofovir induced lichenoid drug eruption
par: Mrinal Gupta, et autres
Publié: (2015) -
A medicinal liver injury with an immunomodulatory drug of natural origin. Case report
par: Elena V. Reznik, et autres
Publié: (2021) -
Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
par: Jingyao Wei, et autres
Publié: (2021) -
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma
par: Li M, et autres
Publié: (2016)